The abstract is read at the publisher; the summary is JClub's.
NAPRT promoter hypermethylation and NAPRT protein loss (<1% staining) occur in 30% to 40% of pediatric rhabdomyosarcoma tumors, linking to strong NAMPTi sensitivity.
- Why it matters: NAMPT inhibitors have preclinical promise but clinical use is constrained by toxicity and the absence of biomarkers that predict who will respond.
- What they did: The study measured NAPRT promoter methylation, transcript, and protein in RMS cells, patient-derived xenografts, and primary tumors (n = 109), then tested NAMPTi sensitivity in isogenic RMS lines and orthotopic PDX models.
- The result: NAPRT-deficient cells were highly sensitive to NAMPTi via NAD+ depletion and NA did not rescue viability or NAMPTi-induced tumor regression in NAPRT-deficient in vivo models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.